TABLE 3.
The delivery, dose and efficacy of lysozyme in diseases.
| Diseases | Treatment protocol | Treatment outcome | Ref |
|---|---|---|---|
| Chemically induced tumors (mice model) | Tumor cells of a 3-methylcholantrene induced tumor inoculated into mice immunized with the same cells treated with HLZ and lethally irradiated | Immunization of mice is successful against tumor development in 42–44% of treatments | Warren et al. (1981) |
| mice bearing Lewis lung carcinoma | Oral administration of 100 mg/kg/day of lysozyme chloride (Lysozyme was administered to mice by supplying the daily amount of lysozyme with the powdered food) | Lysozyme treatment reduces lung metastasis development, by significantly reducing the number of metastases of large dimension (diameters greater than 2 mm) and by causing a significant increase of the percentage of animals free of large metastases, as compared with untreated controls | Sava et al. (1991) |
| Ehrlich-Ascites-Tumor (EAT; mice model) | Peritumoral LZ (8 mg/kg/day) | Tumor cell death and inhibition of DNA synthesis in tumor cells | Choné and Müller, (1968) |
| Adenocarcinoma | LZ treatment of a rat Adenocarcinoma | Inhibition of tumor growth and increase of life-span | Sava et al. (1989) |
| Metastasizing animal tumors (animal model) | LZ to mouse MH134 tumor or to MethA mouse tumor | Inhibition of neoplastic growth of MethA tumors | Fukawa et al. (1982) |
| Intravenous HEWL (50–200 mg/kg/day) on days 1, 5, 10, 15 from intramuscular or intravenous implantation of Lewis lung carcinoma or mammary carcinoma of CBA mouse | 50% reduction of primary tumors: 35–50% and 60–70% reduction of number and weight of metastases, respectively | Sava et al. (1986) | |
| Oral HEWL (12.5–400 mg/kg/day) from tumor implantation to termination (and shorter treatment) in mice with Lewis lung carcinoma | 60% reduction of metastasis weight with 25 mg/kg/day independently of the length of treatment; same action with treatments before tumor implantation | Sava et al. (1988b) | |
| Oral HEWL (35 mg/kg/day) after surgical removal of primary Lewis lung carcinoma tumors | 50% reduction of lung metastases and significant increase of life-span | Sava et al. (1988b) | |
| Oral ELZ (25–100 mg/kg/day for 7days), or plasma and peritoncal resident cells from lysozyme treated mice to mice bearing mammary carcinoma of CBA mouse mammary carcinoma | Significant inhibition of metastatic tumor to about 50% of controls with each treatment performed | Sava et al. (1988a) | |
| BI6 melanoma cells (mice model) | Oral HEWL (50 mg/kg/day) to BD2F1 mice on days 1–7 after the intramuscular implantation of 106 B16 melanoma cells | Significant reduction in the development of lung metastases as compared with that in untreated mice | Sava (1989) |
| Lymphocytoma (mice model) | Intravenous HEWL (100 mg/kg/day) at mice C57Bl/6J with the transplanted ascitic | Significantly potentiates antitumor activity of cyclophosphamide, though it had no effect on the rate of tumor growth | Shcherbakova et al. (2002) |
| Post-transfusion hepatitis | Intravenous lysozyme chloride 60–170 mg/day | Reduced the incidence of hepatitis after transfusion from 20% to 8% | Sato et al. (1981) |
| Chronic crural ulcerations refractory | Local treatment with a solution of ovalbumin lysozyme in normal saline (solution in 0.9% NaCl, 1 mg/ml) | The ulcerations were cleared quickly of pus, granulation tissue developed, the inflammatory reaction around the ulcers decreased and pains were no longer felt | (Gasior-Chrzan 1988; Artym and Zimecki 2013) |
| Abbreviations: LZ = lysozyme. HCL of unspecifid origin; HEWL = Hen egg-white lysozyme | |||